4 Top Growth Stocks Worth Buying Under $100 Today
These four under-the-radar stocks are built to benefit from powerful secular trends that could reward patient, long-term investors.
ENOV - Enovis Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$37.67
DETAILS
HIGH:
$52.00
LOW:
$29.00
MEDIAN:
$32.00
CONSENSUS:
$37.67
UPSIDE:
59.42%
Stock News
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis
ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?
Enovis develops orthopedic and rehabilitation devices for healthcare providers, serving a broad spectrum of musculoskeletal patient needs.
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis Q1 Earnings Call Highlights
Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
Enovis (ENOV) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.81 per share a year ago.
Enovis Announces First Quarter 2026 Results
Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Enovis (ENOV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Enovis Corp (ENOV) a Bargain After 4.7% Drop? GF Value Says Undervalued
On April 28, 2026, Enovis Corp (ENOV) shares fell 4.7% today, closing at $23.40. The stock has experienced a 52-week range of $21.00 to $37.85, indicating signi
Omnicell (OMCL) Q1 Earnings and Revenues Surpass Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.26 per share a year ago.
Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock
Enovis (ENOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Analyst Backs Enovis On Cash Flow Turnaround
The firm argued that while the stock has lagged over the past two years, execution on cash flow could unlock multiple expansion opportunities.
Enovis Corporation (NYSE:ENOV) Receives Consensus Rating of “Buy” from Analysts
Enovis Corporation (NYSE: ENOV - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average
Head to Head Contrast: HeartBeam (NASDAQ:BEAT) versus Enovis (NYSE:ENOV)
HeartBeam (NASDAQ: BEAT - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends. Volatility and Risk HeartBeam has a beta of -0.63,
Enovis to Host First Quarter 2026 Results Conference Call on May 7th
Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com .
Wall Street Analysts See a 100.71% Upside in Enovis (ENOV): Can the Stock Really Move This High?
The consensus price target hints at a 100.7% upside potential for Enovis (ENOV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Royce Small-Cap Fund FY 2025: What Worked
Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.
Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet
The mean of analysts' price targets for Enovis (ENOV) points to a 76.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
American Century Companies Inc. Sells 258,262 Shares of Enovis Corporation $ENOV
American Century Companies Inc. reduced its holdings in shares of Enovis Corporation (NYSE: ENOV) by 5.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,731,065 shares of the company's stock after selling 258,262 shares during the quarter. American Century Companies
Price Targets
Enovis initiated with an Outperform at BMO Capital
$29.00
(was $23.63)
BMO Capital
Enovis price target lowered to $32 from $36 at Evercore ISI
$32.00
(was $24.39)
Evercore ISI
Enovis price target raised to $36 from $35 at Evercore ISI
$36.00
(was $27.27)
Evercore ISI
Enovis Corp (ENOV) PT Raised to $52 at Needham
$52.00
(was $25.42)
Mike Matson
·
Needham
Enovis initiated with a Buy at BTIG
$41.00
(was $27.01)
Ryan Zimmerman
·
BTIG
Enovis price target lowered to $40 from $44 at Evercore ISI
$40.00
(was $26.66)
Evercore ISI
Enovis Corp (ENOV) PT Lowered to $50 at UBS, Estimates Updated
$50.00
(was $27.47)
Danielle Antalffy
·
UBS
Enovis price target lowered to $50 from $58 at Canaccord
$50.00
(was $26.07)
Canaccord Genuity
Needham Reiterates Buy Rating on Enovis Corp (ENOV)
$65.00
(was $43.31)
Mike Matson
·
Needham
Enovis price target lowered to $62 from $70 at Evercore ISI
$62.00
(was $44.35)
Vijay Kumar
·
Evercore ISI
Enovis Corp (ENOV) PT Lowered to $64 at Baird
$64.00
(was $52.13)
Jeff Johnson
·
Robert W. Baird
This Analyst Selects Enovis As Top Pick For 2024: Spotlight On EMPOWR Revision Launch
$70.00
(was $53.58)
Mike Matson
·
Needham
Wells Fargo Upgrades Enovis Corp (ENOV) to Overweight
$67.00
(was $55.79)
Vik Chopra
·
Wells Fargo